- Home
- KMDA vs GPAT Comparison
KMDA vs GPAT Comparison
Compare KMDA & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- GPAT
- Stock Information
- Founded
- KMDA 1990
- GPAT 2020
- Country
- KMDA Israel
- GPAT United States
- Employees
- KMDA N/A
- GPAT N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- GPAT
- Sector
- KMDA Health Care
- GPAT
- Exchange
- KMDA Nasdaq
- GPAT NYSE
- Market Cap
- KMDA 426.0M
- GPAT 365.5M
- IPO Year
- KMDA N/A
- GPAT 2024
- Fundamental
- Price
- KMDA $6.71
- GPAT $10.31
- Analyst Decision
- KMDA Strong Buy
- GPAT
- Analyst Count
- KMDA 3
- GPAT 0
- Target Price
- KMDA $14.67
- GPAT N/A
- AVG Volume (30 Days)
- KMDA 143.8K
- GPAT 14.9K
- Earning Date
- KMDA 03-05-2025
- GPAT 01-01-0001
- Dividend Yield
- KMDA 2.95%
- GPAT N/A
- EPS Growth
- KMDA 66.67
- GPAT N/A
- EPS
- KMDA 0.25
- GPAT 0.34
- Revenue
- KMDA $160,953,000.00
- GPAT N/A
- Revenue This Year
- KMDA $11.45
- GPAT N/A
- Revenue Next Year
- KMDA $9.94
- GPAT N/A
- P/E Ratio
- KMDA $26.22
- GPAT $29.87
- Revenue Growth
- KMDA 12.93
- GPAT N/A
- 52 Week Low
- KMDA $4.74
- GPAT $9.98
- 52 Week High
- KMDA $9.15
- GPAT $10.31
- Technical
- Relative Strength Index (RSI)
- KMDA 44.68
- GPAT N/A
- Support Level
- KMDA $6.44
- GPAT N/A
- Resistance Level
- KMDA $7.17
- GPAT N/A
- Average True Range (ATR)
- KMDA 0.20
- GPAT 0.00
- MACD
- KMDA -0.02
- GPAT 0.00
- Stochastic Oscillator
- KMDA 37.36
- GPAT 0.00
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.